EAU 2024 Annual Meeting
EAU 2024 Prostate Cancer
- EAU 2024: PSA Persistence After Radical Prostatectomy: Optimal Treatment in the Case of PSA Persistence
- EAU 2024: Is All PSA Persistence Created Equal? Definition and Diagnostic Work-Up
- EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What to Test Before Start of Hormonal Treatment and What to Monitor
- EAU 2024: High-Risk Biochemical Recurrence After Radical Prostatectomy and Negative PSMA PET: What to Do? Systemic Therapy Alone
- EAU 2024: High-Risk Biochemical Recurrence after Radical Prostatectomy and Negative PSMA PET: What to Do? The Guideline’s View
EAU 2024 Bladder Cancer
- EAU 2024: Membranous NECTIN-4 Expression in Metastasis Versus Matched Primary Tumor More Accurately Predicts Enfortumab Vedotin Response
- EAU 2024: First-Line Maintenance Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in Routine Care in Germany: Preliminary Results of the Prospective CARAT-UBC Registry
- EAU 2024: TiP: Phase 3 Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)
- EAU 2024: Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer is Associated with High Rates of Adverse Events and Discontinuation of Treatment
- EAU 2024: State-of-the-Art Lecture: New Standard Treatment for Metastatic Bladder Cancer Based on EV-302/KEYNOTE-A39
EAU 2024 Kidney Cancer
- EAU 2024: Moving Towards Intensified Treatment Paradigms in First Line Metastatic Kidney Cancer: Triplet Combinations at Any Cost - Is More Always Better? Yes, the More the Merrier
- EAU 2024: Moving Towards Intensified Treatment Paradigms in First Line Metastatic Kidney Cancer: Triplet Combinations at Any Cost - Is More Always Better? No, Less Is More
- EAU 2024: Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? dCN
- EAU 2024: Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? Upfront CN
- EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? No
EAU 2024 Penile, Urethral, Testicular, and Adrenal Cancers
EAU 2024 Upper Tract Urothelial Carcinoma
- EAU 2024: Urological Follow-up of Lynch Syndrome: Upper Tract Urothelial Carcinoma Incidence and Mutational Patterns in a Dedicated Outpatient Clinic
- EAU 2024: Rapid Fire Debate 6: Patient with Non-Invasive, High Grade Upper Tract Disease in Setting of Prior Radical Cystectomy – What Is Optimal Management? What If GFR ~ 50 Instead of 80?
- EAU 2024: Head-to-Head Comparison of the American Urological Association and European Association of Urology Risk Stratification Models of Upper Tract Urothelial Carcinoma
EAU 2024 Press Releases
- European Association of Urology (EAU) 2024 Congress Features New Data on Modern Technology Use in Bladder Cancer Care
- Oral Vaccine for UTI Is Potential Alternative to Antibiotics, Finds 9-Year Study
- Urine Test Halves Painful Procedures in Bladder Cancer Follow Up, New Trial Shows
- Five-Year Interval Is Safe for Prostate Cancer Screening, Research Shows